You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 15, 2024

VOTRIENT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Votrient, and when can generic versions of Votrient launch?

Votrient is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in VOTRIENT is pazopanib hydrochloride. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the pazopanib hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Votrient

A generic version of VOTRIENT was approved as pazopanib hydrochloride by APOTEX on October 19th, 2023.

  Try a Trial

Drug patent expirations by year for VOTRIENT
Drug Prices for VOTRIENT

See drug prices for VOTRIENT

Recent Clinical Trials for VOTRIENT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Centre Leon BerardPhase 1/Phase 2
National Cancer Institute, FrancePhase 1/Phase 2
North Eastern German Society of Gynaecological OncologyPhase 2

See all VOTRIENT clinical trials

US Patents and Regulatory Information for VOTRIENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VOTRIENT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VOTRIENT

See the table below for patents covering VOTRIENT around the world.

Country Patent Number Title Estimated Expiration
Germany 60138645 ⤷  Try a Trial
European Patent Office 1343782 COMPOSES CHIMIQUES (PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS) ⤷  Try a Trial
Hong Kong 1059926 ⤷  Try a Trial
South Korea 20040011448 ⤷  Try a Trial
Portugal 2311825 ⤷  Try a Trial
Japan 4253188 ⤷  Try a Trial
Hong Kong 1149930 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VOTRIENT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1343782 10C0037 France ⤷  Try a Trial PRODUCT NAME: PAZOPANIB; REGISTRATION NO/DATE: EU/1/110/628/001 20100614
1343782 C01343782/01 Switzerland ⤷  Try a Trial FORMER OWNER: GLAXOSMITHKLINE LLC, US
1343782 C300456 Netherlands ⤷  Try a Trial PRODUCT NAME: PAZOPANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER PAZOPANIB HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614
1343782 91710 Luxembourg ⤷  Try a Trial 91710, EXPIRES: 20250614
1343782 SPC025/2010 Ireland ⤷  Try a Trial SPC025/2010: 20110401, EXPIRES: 20250613
1343782 389 Finland ⤷  Try a Trial
1343782 2010C/030 Belgium ⤷  Try a Trial PRODUCT NAME: PAZOPANIB, OPTIONNELLEMENT SOUS LA FORME DE SON SEL PHARMACEUTIQUEMENT ACCEPTABLE OU DE SON SOLVATE; AUTHORISATION NUMBER AND DATE: EU/1/110/628/01 20100616
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.